Projet PvSTATEM

Résumé de l’activité

Malaria eradication requires addressing all malaria species, including Plasmodium vivax that resists elimination efforts because of its dormant liver forms (“hypnozoites”). These forms cannot be detected with traditional methods, but they can reactivate (“relapse infection”) causing illness and new transmission from people to mosquitoes. The P. vivax Serological Testing and Treatment in Ethiopia and Madagascar (PvSTATEM) project aims to address this challenge. We have developed a diagnostic test to identify people likely to carry hypnozoites and target them for treatment to clear hypnozoites and prevent relapse infection. This combination of a novel diagnostic test and primaquine treatment provides a new intervention for malaria control and elimination. In PvSTATEM we plan to assess the efficacy, safety, and acceptability of this new intervention of serological testing & treatment (objectives 1 & 2), as well as to develop digital approaches for better implementation (objective 3) and machine learning tools for malaria surveillance at the level of entire populations (objective 4). This Horizon Europe-funded project started in late 2022, under the coordination of Institut Pasteur and the London School of Hygiene and Tropical Medicine, with clinical trials in Ethiopia and Madagascar and key partners in 9 countries worldwide. The project is built on equal partnership and shared capacity to address a substantial public health burden.

Disclaimer: Funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.